Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval
Executive Summary
Expanded US approval for Alecensa in ALK-positive NSCLC will stand the product in good stead as it helps make up for upcoming biosimilar threat to Avastin, Rituxan and Herceptin.
You may also be interested in...
Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?
Takeda's Phase III win over Pfizer's Xalkori leaves oncologists cheering, but hankering for a head-to-head study against Alecensa, which is becoming the standard of care in the US for first-line ALK+ NSCLC.
Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice
With Flatiron, Roche is at the forefront of the emerging field of RWE. Roche Pharma President O’Day described how the company is using such data in the real world of regulation and reimbursement.
Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology
Roche used its ASCO investor briefing to highlight its digital and personalized healthcare strategy, including examples of how it’s facilitating R&D and reimbursement – and how that should position it to be an oncology leader in the future.